Webcast CME

Mastering the Treatment of Myeloid
Malignancies in the Era of Personalized
Medicine

Targeted Treatment Strategies for AML: Concept of Measurable Residual Disease (MRD) and Management of Treatment-related Adverse Events

Print this Content

Release date: January 22, 2021
Expiration date: January 22, 2023

Estimated Time of Completion: 30 minutes

Description

Cleveland Clinic and Aplastic Anemia & MDS International Foundation present Targeted Treatment Strategies for AML: Concept of Measurable Residual Disease (MRD) and Management of Treatment-related Adverse Events, part of the Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine online series, will provide an in-depth review of myeloproliferative neoplasms, risk stratification, prognostic implications, and treatment options.

Learning Objectives

  1. Define the specific indications for targeted therapies in patients with acute myeloid leukemia (AML), concept of minimal residual disease in AML, and management strategies for adverse events related to novel therapies.

Target Audience

This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors, Planning Committee and Faculty

Activity Co-Directors

Bhumika Patel, MD
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Sudipto Mukherjee, MD, PhD, MPH
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Faculty

Jeffrey E. Lancet, MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:


Jeffrey Lancet, MD
  Abbvie Pharmaceuticals, Astellas Pharma US, Inc., ElevateBio, Agios Pharmaceuticals, Guidepoint Global Consulting
  Medscape Teaching and Speaking
  Daiichi Sankyo, Inc. Membership on advisory committee or review panels
Sudipto Mukherjee, MD, PhD, MPH
  Celgene Corporation, a Bristol-Myers Squibb company Board Membership
Consulting
Research / Independent Contractor
Membership on advisory committee or review panels
Research Funding - non-therapeutic investigator trials
  Novartis Consulting
Membership on advisory committee or review panels
Research Funding
  Accerleron Pharma Inc. Membership on advisory committee or review panels
  BioPharm Consulting
  Bristol-Myers Squibb Co. Honoraria
  McGraw Hill Honoraria - Editor of Hematology
Oncology Board Review
  Partnership for Health Analytic Research, LLC (PHAR, LLC) Consulting
Bhumika Patel, MD
  Alexion Teaching and Speaking
  Novartis Membership on advisory committee or review panels


Acknowledgment

The Aplastic Anemia and MDS International Foundation and Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:

Bristol-Myers Squibb
Geron Corporation

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.